2
ALL2
Phoenix BiotechnologyYear
2
ALL1
20211
2020DEALS // DEV.
2
ALL2
DevelopmentsCountry
2
ALL2
U.S.A2
ALL2
InapplicableTherapeutic Area
2
ALL2
Infections and Infectious DiseasesStudy Phase
2
ALL2
PreclinicalDeal Type
2
ALL2
InapplicableProduct Type
2
ALL2
Other Small MoleculeDosage Form
2
ALL2
UndisclosedLead Product
2
ALL2
OleandrinTarget
2
ALL2
UndisclosedLead Product(s) : Oleandrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The in vitro study, using Vero cells, found that “prophylactic oleandrin (as either the pure compound or as the active principal ingredient in PBI-06150) administration at concentrations as low as 0.05 μg/ml exhibited potent antiviral activity against...
Product Name : PBI-05204
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2021
Lead Product(s) : Oleandrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oleandrin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Published reports from in vitro cell culture studies have shown that oleandrin and extracts containing this molecule are effective against HIV, the Ebola virus as well as HTLV-1 and other viruses that are harmful to human health and well-being.
Product Name : PBI-05204
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Oleandrin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable